Annovis Bio, Inc. announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer's disease (AD). A total of 327 patients have successfully concluded the phase II/III trial out of the initial 353 enrolled.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.55 USD | +9.17% | -10.15% | -64.97% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.97% | 73.17M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.26% | 21.96B | |
-8.07% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease